P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series

P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series

Abstract Background Vestibular Schwannoma (VS) causes loss of hearing, loss of balance, tinnitus and even may lead to facial numbness. Various treatment choices have been increasing such as surgery, fractionated stereotactic radiotherapy (FSRT), Gamma Knife radiosurgery (GKRS), single fraction linac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2018-09, Vol.20 (suppl_3), p.iii317-iii318
Hauptverfasser: Nghia, T L B, Y, M N, Morra, M E, Vuong, N L, Tin, N M, Karam, D, Refaey, M A, Shahin, K, Soliman, A L, Huy, N T
Format: Artikel
Sprache:eng
Schlagworte:
Poster Presentations
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page iii318
container_issue suppl_3
container_start_page iii317
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 20
creator Nghia, T L B
Y, M N
Morra, M E
Vuong, N L
Tin, N M
Karam, D
Refaey, M A
Shahin, K
Soliman, A L
Huy, N T
description Abstract Background Vestibular Schwannoma (VS) causes loss of hearing, loss of balance, tinnitus and even may lead to facial numbness. Various treatment choices have been increasing such as surgery, fractionated stereotactic radiotherapy (FSRT), Gamma Knife radiosurgery (GKRS), single fraction linac stereotactic radiosurgery (SFSRT) and conservative treatment. However, there is no conclusive evidence about the best treatment of VS. In this study, we aimed to systematically review and meta-analyze all possible strategies for management of VS. Material and Methods We conducted a systematic electronic search in 13 electronic databases; PubMed, ScienceDirect, WHO Global Health Library, Virtual Health Library (VHL), Scopus, The Institute of Science Index (ISI), Google Scholar, Clinical trials, Controlled Trials (MRCT), Cochrane, System for Information on Grey Literature in Europe (SIGLE), EMBASE, New York Academy of Medicine Grey Literature Report (NYAM) database for relevant studies. Original studies and case series reporting treatment of VS were included. Meta-analysis with random effects models was performed for the outcomes of tumor size reduction, increase in hearing capability, and complications. Results We included 48 studies including 3531 participants. The pooled proportions and 95% confidence intervals (95%-CIs) for tumor size reduction using FSRT and GKRS were 0.34 (0.20; 0.51) and 0.53 (0.40; 0.65), respectively. The proportions and 95%-CÍs of increase in hearing capability using surgery, FSRT, and GKRS were 0.11 (0.0; 0.91); 0.08 (0.05; 0.11), and 0.08 (0.05; 0.13), respectively. The pooled proportions of complications of surgery, FSRT, GKRS, and SFSRT were 0.18 (0.10; 0.30); 0.15 (0.08; 0.24); 0.21 (0.14; 0.30); and 0.32 (0.12; 0.24), respectively. Conclusion Our study highlights the efficacy and safety of different treatments for VS such as surgery, FSRT, GKRS, and SFSRT. However, there are no controlled trials to compare these different remedies. Future large scale randomized controlled trials are needed to clarify.
doi_str_mv 10.1093/neuonc/noy139.389
format Article
fullrecord <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6144431</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noy139.389</oup_id><sourcerecordid>10.1093/neuonc/noy139.389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1779-d5dc9c07e9d63eaa900cd4325515e94b6b47625eee437e63856166850446bb993</originalsourceid><addsrcrecordid>eNqNkF9LwzAUxYsoOKcfwLd8ALslzZ82PghS_AeC4qavIU1vXaRNRtJt7NtbrQi--XQv595z4PyS5JzgGcGSzh1svDNz5_eEyhkt5EEyITyjKS-EOPzes7TgJD9OTmL8wDgjXJBJYp8xnwmKlitAFcQe9QF034HrUeMDehskW21aHdDCrHbaOd_pS7TYxx463VuDXmBrYYd8g8rWOmt0i5bB6jYi7WpU6ghoAcFCPE2OmkGGs585TV5vb5blffr4dPdQXj-mhuS5TGteG2lwDrIWFLSWGJua0YxzwkGySlQsFxkHAEZzELQYaghRcMyYqCop6TS5GnPXm6qD2gxVgm7VOthOh73y2qq_F2dX6t1vlSCMMUqGADIGmOBjDND8eglWX7DVCFuNsNUAe_BcjB6_Wf_j_RMwxYVv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nghia, T L B ; Y, M N ; Morra, M E ; Vuong, N L ; Tin, N M ; Karam, D ; Refaey, M A ; Shahin, K ; Soliman, A L ; Huy, N T</creator><creatorcontrib>Nghia, T L B ; Y, M N ; Morra, M E ; Vuong, N L ; Tin, N M ; Karam, D ; Refaey, M A ; Shahin, K ; Soliman, A L ; Huy, N T</creatorcontrib><description>Abstract Background Vestibular Schwannoma (VS) causes loss of hearing, loss of balance, tinnitus and even may lead to facial numbness. Various treatment choices have been increasing such as surgery, fractionated stereotactic radiotherapy (FSRT), Gamma Knife radiosurgery (GKRS), single fraction linac stereotactic radiosurgery (SFSRT) and conservative treatment. However, there is no conclusive evidence about the best treatment of VS. In this study, we aimed to systematically review and meta-analyze all possible strategies for management of VS. Material and Methods We conducted a systematic electronic search in 13 electronic databases; PubMed, ScienceDirect, WHO Global Health Library, Virtual Health Library (VHL), Scopus, The Institute of Science Index (ISI), Google Scholar, Clinical trials, Controlled Trials (MRCT), Cochrane, System for Information on Grey Literature in Europe (SIGLE), EMBASE, New York Academy of Medicine Grey Literature Report (NYAM) database for relevant studies. Original studies and case series reporting treatment of VS were included. Meta-analysis with random effects models was performed for the outcomes of tumor size reduction, increase in hearing capability, and complications. Results We included 48 studies including 3531 participants. The pooled proportions and 95% confidence intervals (95%-CIs) for tumor size reduction using FSRT and GKRS were 0.34 (0.20; 0.51) and 0.53 (0.40; 0.65), respectively. The proportions and 95%-CÍs of increase in hearing capability using surgery, FSRT, and GKRS were 0.11 (0.0; 0.91); 0.08 (0.05; 0.11), and 0.08 (0.05; 0.13), respectively. The pooled proportions of complications of surgery, FSRT, GKRS, and SFSRT were 0.18 (0.10; 0.30); 0.15 (0.08; 0.24); 0.21 (0.14; 0.30); and 0.32 (0.12; 0.24), respectively. Conclusion Our study highlights the efficacy and safety of different treatments for VS such as surgery, FSRT, GKRS, and SFSRT. However, there are no controlled trials to compare these different remedies. Future large scale randomized controlled trials are needed to clarify.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noy139.389</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Poster Presentations</subject><ispartof>Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii317-iii318</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144431/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144431/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1584,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Nghia, T L B</creatorcontrib><creatorcontrib>Y, M N</creatorcontrib><creatorcontrib>Morra, M E</creatorcontrib><creatorcontrib>Vuong, N L</creatorcontrib><creatorcontrib>Tin, N M</creatorcontrib><creatorcontrib>Karam, D</creatorcontrib><creatorcontrib>Refaey, M A</creatorcontrib><creatorcontrib>Shahin, K</creatorcontrib><creatorcontrib>Soliman, A L</creatorcontrib><creatorcontrib>Huy, N T</creatorcontrib><title>P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract Background Vestibular Schwannoma (VS) causes loss of hearing, loss of balance, tinnitus and even may lead to facial numbness. Various treatment choices have been increasing such as surgery, fractionated stereotactic radiotherapy (FSRT), Gamma Knife radiosurgery (GKRS), single fraction linac stereotactic radiosurgery (SFSRT) and conservative treatment. However, there is no conclusive evidence about the best treatment of VS. In this study, we aimed to systematically review and meta-analyze all possible strategies for management of VS. Material and Methods We conducted a systematic electronic search in 13 electronic databases; PubMed, ScienceDirect, WHO Global Health Library, Virtual Health Library (VHL), Scopus, The Institute of Science Index (ISI), Google Scholar, Clinical trials, Controlled Trials (MRCT), Cochrane, System for Information on Grey Literature in Europe (SIGLE), EMBASE, New York Academy of Medicine Grey Literature Report (NYAM) database for relevant studies. Original studies and case series reporting treatment of VS were included. Meta-analysis with random effects models was performed for the outcomes of tumor size reduction, increase in hearing capability, and complications. Results We included 48 studies including 3531 participants. The pooled proportions and 95% confidence intervals (95%-CIs) for tumor size reduction using FSRT and GKRS were 0.34 (0.20; 0.51) and 0.53 (0.40; 0.65), respectively. The proportions and 95%-CÍs of increase in hearing capability using surgery, FSRT, and GKRS were 0.11 (0.0; 0.91); 0.08 (0.05; 0.11), and 0.08 (0.05; 0.13), respectively. The pooled proportions of complications of surgery, FSRT, GKRS, and SFSRT were 0.18 (0.10; 0.30); 0.15 (0.08; 0.24); 0.21 (0.14; 0.30); and 0.32 (0.12; 0.24), respectively. Conclusion Our study highlights the efficacy and safety of different treatments for VS such as surgery, FSRT, GKRS, and SFSRT. However, there are no controlled trials to compare these different remedies. Future large scale randomized controlled trials are needed to clarify.</description><subject>Poster Presentations</subject><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkF9LwzAUxYsoOKcfwLd8ALslzZ82PghS_AeC4qavIU1vXaRNRtJt7NtbrQi--XQv595z4PyS5JzgGcGSzh1svDNz5_eEyhkt5EEyITyjKS-EOPzes7TgJD9OTmL8wDgjXJBJYp8xnwmKlitAFcQe9QF034HrUeMDehskW21aHdDCrHbaOd_pS7TYxx463VuDXmBrYYd8g8rWOmt0i5bB6jYi7WpU6ghoAcFCPE2OmkGGs585TV5vb5blffr4dPdQXj-mhuS5TGteG2lwDrIWFLSWGJua0YxzwkGySlQsFxkHAEZzELQYaghRcMyYqCop6TS5GnPXm6qD2gxVgm7VOthOh73y2qq_F2dX6t1vlSCMMUqGADIGmOBjDND8eglWX7DVCFuNsNUAe_BcjB6_Wf_j_RMwxYVv</recordid><startdate>20180919</startdate><enddate>20180919</enddate><creator>Nghia, T L B</creator><creator>Y, M N</creator><creator>Morra, M E</creator><creator>Vuong, N L</creator><creator>Tin, N M</creator><creator>Karam, D</creator><creator>Refaey, M A</creator><creator>Shahin, K</creator><creator>Soliman, A L</creator><creator>Huy, N T</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20180919</creationdate><title>P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series</title><author>Nghia, T L B ; Y, M N ; Morra, M E ; Vuong, N L ; Tin, N M ; Karam, D ; Refaey, M A ; Shahin, K ; Soliman, A L ; Huy, N T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1779-d5dc9c07e9d63eaa900cd4325515e94b6b47625eee437e63856166850446bb993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Poster Presentations</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nghia, T L B</creatorcontrib><creatorcontrib>Y, M N</creatorcontrib><creatorcontrib>Morra, M E</creatorcontrib><creatorcontrib>Vuong, N L</creatorcontrib><creatorcontrib>Tin, N M</creatorcontrib><creatorcontrib>Karam, D</creatorcontrib><creatorcontrib>Refaey, M A</creatorcontrib><creatorcontrib>Shahin, K</creatorcontrib><creatorcontrib>Soliman, A L</creatorcontrib><creatorcontrib>Huy, N T</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nghia, T L B</au><au>Y, M N</au><au>Morra, M E</au><au>Vuong, N L</au><au>Tin, N M</au><au>Karam, D</au><au>Refaey, M A</au><au>Shahin, K</au><au>Soliman, A L</au><au>Huy, N T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2018-09-19</date><risdate>2018</risdate><volume>20</volume><issue>suppl_3</issue><spage>iii317</spage><epage>iii318</epage><pages>iii317-iii318</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract Background Vestibular Schwannoma (VS) causes loss of hearing, loss of balance, tinnitus and even may lead to facial numbness. Various treatment choices have been increasing such as surgery, fractionated stereotactic radiotherapy (FSRT), Gamma Knife radiosurgery (GKRS), single fraction linac stereotactic radiosurgery (SFSRT) and conservative treatment. However, there is no conclusive evidence about the best treatment of VS. In this study, we aimed to systematically review and meta-analyze all possible strategies for management of VS. Material and Methods We conducted a systematic electronic search in 13 electronic databases; PubMed, ScienceDirect, WHO Global Health Library, Virtual Health Library (VHL), Scopus, The Institute of Science Index (ISI), Google Scholar, Clinical trials, Controlled Trials (MRCT), Cochrane, System for Information on Grey Literature in Europe (SIGLE), EMBASE, New York Academy of Medicine Grey Literature Report (NYAM) database for relevant studies. Original studies and case series reporting treatment of VS were included. Meta-analysis with random effects models was performed for the outcomes of tumor size reduction, increase in hearing capability, and complications. Results We included 48 studies including 3531 participants. The pooled proportions and 95% confidence intervals (95%-CIs) for tumor size reduction using FSRT and GKRS were 0.34 (0.20; 0.51) and 0.53 (0.40; 0.65), respectively. The proportions and 95%-CÍs of increase in hearing capability using surgery, FSRT, and GKRS were 0.11 (0.0; 0.91); 0.08 (0.05; 0.11), and 0.08 (0.05; 0.13), respectively. The pooled proportions of complications of surgery, FSRT, GKRS, and SFSRT were 0.18 (0.10; 0.30); 0.15 (0.08; 0.24); 0.21 (0.14; 0.30); and 0.32 (0.12; 0.24), respectively. Conclusion Our study highlights the efficacy and safety of different treatments for VS such as surgery, FSRT, GKRS, and SFSRT. However, there are no controlled trials to compare these different remedies. Future large scale randomized controlled trials are needed to clarify.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noy139.389</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii317-iii318
issn 1522-8517
1523-5866
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6144431
source Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Poster Presentations
title P05.63 The best treatment for Vestibular Schwannoma: Systematic Review of Clinical Trials and Case Series
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T21%3A26%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P05.63%20The%20best%20treatment%20for%20Vestibular%20Schwannoma:%20Systematic%20Review%20of%20Clinical%20Trials%20and%20Case%20Series&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Nghia,%20T%20L%20B&rft.date=2018-09-19&rft.volume=20&rft.issue=suppl_3&rft.spage=iii317&rft.epage=iii318&rft.pages=iii317-iii318&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noy139.389&rft_dat=%3Coup_pubme%3E10.1093/neuonc/noy139.389%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noy139.389&rfr_iscdi=true